Moreover, as the majority of patients with NF1 develop non-tumor-related comorbidities (e.g. cognitive deficits), a subset of which are not dependent on RAS-MEK activity, the identification of RAS-independent targetable proteins or pathways will be critical for their management. This evidence concerns the gene NF1 and neoplasm.